共 218 条
[1]
Satman I(2013)TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults Eur J Epidemiol 28 169-180
[2]
Omer B(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589
[3]
Tutuncu Y(2008)ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2560-2572
[4]
Kalaca S(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 352 837-853
[5]
Gedik S(2018)Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany Diabetes Obes Metab 20 389-399
[6]
Dinccag N(2018)Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 61 2461-2498
[7]
Holman RR(2014)A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor Diabetes Metab J 38 261-273
[8]
Paul SK(2014)Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Drug Des Devel Ther 8 1335-1380
[9]
Bethel MA(2017)Addition of Ipragliflozin to metformin treatment in Korean patients with type 2 diabetes mellitus: subgroup analysis of a phase 3 trial Diabetes Metab J 41 135-145
[10]
Matthews DR(2018)Characteristics of dapagliflozin responders: A longitudinal, prospective, nationwide dapagliflozin surveillance study in Korea Diabetes Ther 9 1689-1701